Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Clinical and forensic toxicology - Insights
Clinical, forensic, and emergency toxicology testing at Mayo Clinic Laboratories, which aligns with evidence-based clinical laboratory guidelines, uses advanced and emerging technologies and is performed on urine, serum, and meconium...
Thrombotic Microangiopathies (TMA) [Test in Focus] - Insights
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to...
Neurofascin 155 IgG4 Antibody Test [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of...
Mayo Clinic and National Decision Support Company unveil CareSelect Lab™ to provide real-time medical guidance when ordering clinical lab tests. The tool assists health care providers with appropriate ordering of lab testing, improving...
Autoimmune Myelopathy Testing - Mayo Clinic Laboratories
Mayo Clinic Laboratories is the only laboratory in the world to offer testing for a novel form of autoimmune meningoencephalomyelitis.
We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.
Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.
Lung Cancer NGS Panel - Mayo Clinic Laboratories
Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.
Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.